Last reviewed · How we verify
NCT04314232: COVID MECH
Mechanisms for Covid-19 Disease Complications
trial in COVID in 200 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | University Hospital, Akershus |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 18 March 2020 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Norway |
Conditions studied
- COVID — all drugs for COVID →
- Coronavirus Infection — all drugs for Coronavirus Infection →
Sponsor
University Hospital, Akershus
Who can join
18 and older, any sex, with COVID or Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Covid-19 is associated with a wide range of symptoms and clinical trajectories, and early identification of patients at risk for developing severe disease is desirable. Several risk markers and comorbidity profiles have been proposed but their relative importance in unselected patients admitted to hospital with Covid-19 remains unclear. This study aims to assess the prognostic value organ specific biomarkers, viral dynamics and immune response markers in patients infected with SARS-CoV2.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19.
Myhre PL, Prebensen C, Strand H, Røysland R, et al · · 2020 · cited 91× · PMID 33058695 · DOI 10.1161/circulationaha.120.050360 -
Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Plasma Is Associated With Intensive Care Unit Admission and Mortality in Patients Hospitalized With Coronavirus Disease 2019.
Prebensen C, Myhre PL, Jonassen C, Rangberg A, et al · · 2021 · cited 71× · PMID 32888003 · DOI 10.1093/cid/ciaa1338 -
Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity.
Myhre PL, Heck SL, Skranes JB, Prebensen C, et al · · 2021 · cited 25× · PMID 34400140 · DOI 10.1016/j.ahj.2021.08.001 -
Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19.
Omland T, Prebensen C, Røysland R, Søvik S, et al · · 2020 · cited 22× · PMID 32910681 · DOI 10.1161/circulationaha.120.050089 -
SARS-CoV-2 Viremia is Associated With Inflammatory, But Not Cardiovascular Biomarkers, in Patients Hospitalized for COVID-19.
Myhre PL, Prebensen C, Jonassen CM, Berdal JE, et al · · 2021 · cited 21× · PMID 33596668 · DOI 10.1161/jaha.120.019756 -
Soluble ST2 concentrations associate with in-hospital mortality and need for mechanical ventilation in unselected patients with COVID-19.
Omland T, Prebensen C, Jonassen C, Svensson M, et al · · 2021 · cited 15× · PMID 34933965 · DOI 10.1136/openhrt-2021-001884 -
A single-centre, prospective cohort study of COVID-19 patients admitted to ICU for mechanical ventilatory support.
Søvik S, Bådstøløkken PM, Sørensen V, Myhre PL, et al · · 2021 · cited 13× · PMID 33128800 · DOI 10.1111/aas.13726 -
Minor Myocardial Scars in Association with Cardiopulmonary Function after COVID-19.
Øvrebotten T, Heck S, Skjørten I, Einvik G, et al · · 2023 · cited 1× · PMID 37231850 · DOI 10.1159/000530942
Verify or expand the search:
- PubMed search for NCT04314232
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID
Currently open trials in the same condition.
- NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
- NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
- NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
Other University Hospital, Akershus trials
Trials by the same sponsor.
- NCT06865027 — The Effect of Arterial Carbon Dioxide Levels on Cerebral Blood Flow and Cerebral Autoregulation in the Steep Trendelenbu · NA · enrolling by invitation
- NCT06721754 — Diabetes Related Foot Ulcers with Negative Pressure Wound Therapy · NA · recruiting
- NCT06731985 — The Follow-up After Shorter Tapes Study. Effectiveness and Safety of Shorter Trans-obturator Tapes. · recruiting
- NCT06576752 — Management of Patients with Heart Failure At Home After Hospital Discharge · NA · recruiting
- NCT06032715 — Brief Intervention for Sleep Medication Misuse Among Elderly · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04314232 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Akershus
- Last refreshed: 26 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04314232.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing